secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0000950170-24-134765
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro selects luvelta dose for registrational ovarian cancer trial; 32% ORR in Part 1
--------------------------------------------------------------------------------

- Selected dose: 5.2 mg/kg with prophylactic pegfilgrastim for 2 cycles then 4.3 mg/kg for subsequent cycles.
- Topline Part 1 (5.2 mg/kg, N=25): ORR 32%, DCR 96%; half of patients ineligible for approved FRα-targeting ADC.
- 88% of patients received prior bevacizumab; Grade 3+ neutropenia 32%, no febrile neutropenia.
- Part 2 registrational trial to enroll ~500 patients randomized 1:1 luvelta vs investigator's choice chemo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017024134765/0000950170-24-134765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017024134765/stro-20241210.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-134765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer